SCHEMBL6749699

SCHEMBL6749699

CC(C)(C)OC(=O)NCc1nccn1COCC[Si](C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
GFER P55789 3/20 0.40
DGAT1 O75907 2/20 0.38
L3MBTL1 Q9Y468 3/20 0.37
HSD17B10 Q99714 1/20 0.37
BRD4 O60885 1/20 0.37
PCSK9 Q8NBP7 1/20 0.37
POLB P06746 1/20 0.36
MAPK1 P28482 1/20 0.36
ATM Q13315 1/20 0.36
ALDH1A1 P00352 1/20 0.35
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA9 Q16790 2/20 0.35
AKT1 P31749 1/20 0.35
FPR2 P25090 1/20 0.34
NAMPT P43490 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3843734 0.85 SUCNR1 (0.37) KDM4ELMNAGFERALDH1A1
SCHEMBL6747810 0.84 FPR2 (0.37) DGAT1FPR2
SCHEMBL24509637 0.82 CYP17A1 (0.39) DGAT1BRD4PCSK9FPR2
SCHEMBL1792504 0.80 DGAT1 (0.35) DGAT1L3MBTL1FPR2
SCHEMBL17282958 0.79 KDM4E (0.35) KDM4EDGAT1PCSK9FPR2
SCHEMBL18681721 0.78 FPR2 (0.37) KDM4EDGAT1PCSK9CA1CA2
SCHEMBL14852930 0.78 ADRA2C (0.48) DGAT1FPR2
SCHEMBL3170401 0.76 DGAT1 (0.33) DGAT1FPR2
SCHEMBL4206991 0.76 KLKB1 (0.33) DGAT1FPR2
SCHEMBL5767975 0.76 SSTR4 (0.35) DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092737-A1 Benzopiperidine derivatives EISAI CO., LTD. 2004-05-13 US disclosed
US-6518423-B1 These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and EISAI CO., LTD. (JP) 2003-02-11 US disclosed
EP-0934941-A1 BENZOPIPERIDINE DERIVATIVES Eisai Co., Ltd. (JP) 1999-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092737-A1 Benzopiperidine derivatives HLA-DRB1, HRH1, HRH2 KDM4E 1573/4885LMNA 4878/4885GFER 4035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.